IL2 and neuroblastoma: Further, the combination of the chimeric antibody ch14.18 dinutuximab with the granulocyte–macrophage colony-stimulating factor (GM-CSF) or interleukin-2 (IL2) has demonstrated significantly improved 2-year event-free survival in high-risk neuroblastoma patients (9).